Literature DB >> 19103439

Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis.

William T Regenold1, Pornima Phatak, Christopher M Marano, Amritpal Sassan, Robert R Conley, Mitchel A Kling.   

Abstract

BACKGROUND: Evidence is accumulating that mitochondrial dysfunction is involved in the pathophysiology of bipolar disorder and schizophrenia. Cerebrospinal fluid (CSF) concentration of lactate, a product of extra-mitochondrial glucose metabolism, is commonly elevated in individuals with mitochondrial disorders, especially those with neuropsychiatric symptoms. We tested the hypothesis that patients with bipolar disorder and schizophrenia would, on average, have elevated CSF lactate concentrations compared with healthy control subjects.
METHODS: The CSF lactate and CSF and plasma glucose concentrations were measured with a YSI (YSI, Yellow Springs, Ohio) 2300 STAT Plus Glucose & Lactate Analyzer in 15 samples from each of three groups of subjects: bipolar I disorder patients, schizophrenic patients, and healthy control subjects.
RESULTS: Mean CSF lactate concentrations were significantly higher in bipolar (1.76 +/- .38) and schizophrenic subjects (1.61 +/- .31) compared with control subjects (1.31 +/- .21 mmol/L). These differences persisted after adjusting means for CSF glucose concentration, which correlated positively with CSF lactate concentration.
CONCLUSIONS: This is the first report of increased CSF lactate concentrations in patients with bipolar disorder and schizophrenia. Elevated CSF lactate indicates increased extra-mitochondrial and anaerobic glucose metabolism and is consistent with impaired mitochondrial metabolism. Measuring CSF lactate concentration might help identify bipolar and schizophrenic patients with mitochondrial dysfunction who might benefit from research to elucidate and ultimately rectify possible mitochondrial pathology underlying these disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19103439      PMCID: PMC3752997          DOI: 10.1016/j.biopsych.2008.11.010

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  41 in total

Review 1.  The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.

Authors:  G S Sachs; D J Printz; D A Kahn; D Carpenter; J P Docherty
Journal:  Postgrad Med       Date:  2000-04       Impact factor: 3.840

2.  Association of bipolar disorder with the 5178 polymorphism in mitochondrial DNA.

Authors:  T Kato; H Kunugi; S Nanko; N Kato
Journal:  Am J Med Genet       Date:  2000-04-03

3.  Altered brain energy metabolism in lithium-resistant bipolar disorder detected by photic stimulated 31P-MR spectroscopy.

Authors:  J Murashita; T Kato; T Shioiri; T Inubushi; N Kato
Journal:  Psychol Med       Date:  2000-01       Impact factor: 7.723

4.  Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress.

Authors:  Alipi V Naydenov; Matthew L MacDonald; Dost Ongur; Christine Konradi
Journal:  Arch Gen Psychiatry       Date:  2007-05

Review 5.  Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder.

Authors:  Jorge A Quiroz; Neil A Gray; Tadafumi Kato; Husseini K Manji
Journal:  Neuropsychopharmacology       Date:  2008-01-30       Impact factor: 7.853

Review 6.  Mitochondrial involvement in psychiatric disorders.

Authors:  Ling Shao; Maureen V Martin; Stanley J Watson; Alan Schatzberg; Huda Akil; Richard M Myers; Edward G Jones; William E Bunney; Marquis P Vawter
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

7.  Increased lactate levels and reduced pH in postmortem brains of schizophrenics: medication confounds.

Authors:  Nader D Halim; Barbara K Lipska; Thomas M Hyde; Amy Deep-Soboslay; E Michael Saylor; Mary M Herman; Jay Thakar; Ajay Verma; Joel E Kleinman
Journal:  J Neurosci Methods       Date:  2007-11-29       Impact factor: 2.390

Review 8.  Brain magnetic resonance in the diagnostic evaluation of mitochondrial encephalopathies.

Authors:  Maria Cristina Bianchi; Giuseppina Sgandurra; Michela Tosetti; Roberta Battini; Giovanni Cioni
Journal:  Biosci Rep       Date:  2007-06       Impact factor: 3.840

9.  Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function.

Authors:  M Kvajo; A Dhilla; D E Swor; M Karayiorgou; J A Gogos
Journal:  Mol Psychiatry       Date:  2007-08-07       Impact factor: 15.992

10.  Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia.

Authors:  Elaine Holmes; Tsz M Tsang; Jeffrey T-J Huang; F Markus Leweke; Dagmar Koethe; Christoph W Gerth; Brit M Nolden; Sonja Gross; Daniela Schreiber; Jeremy K Nicholson; Sabine Bahn
Journal:  PLoS Med       Date:  2006-08       Impact factor: 11.069

View more
  58 in total

1.  Noninvasive quantification of ascorbate and glutathione concentration in the elderly human brain.

Authors:  Uzay E Emir; Susan Raatz; Susan McPherson; James S Hodges; Carolyn Torkelson; Pierre Tawfik; Tonya White; Melissa Terpstra
Journal:  NMR Biomed       Date:  2011-01-12       Impact factor: 4.044

Review 2.  Staging and neuroprogression in bipolar disorder.

Authors:  Gabriel Rodrigo Fries; Bianca Pfaffenseller; Laura Stertz; André Vinicius Contri Paz; Aroldo Ayub Dargél; Maurício Kunz; Flávio Kapczinski
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

3.  Frontal lobe bioenergetic metabolism in depressed adolescents with bipolar disorder: a phosphorus-31 magnetic resonance spectroscopy study.

Authors:  Xian-Feng Shi; Douglas G Kondo; Young-Hoon Sung; Tracy L Hellem; Kristen K Fiedler; Eun-Kee Jeong; Rebekah S Huber; Perry F Renshaw
Journal:  Bipolar Disord       Date:  2012-07-20       Impact factor: 6.744

Review 4.  Mitochondrial Oxidative Phosphorylation System (OXPHOS) Deficits in Schizophrenia: Possible Interactions with Cellular Processes.

Authors:  Oded Bergman; Dorit Ben-Shachar
Journal:  Can J Psychiatry       Date:  2016-08       Impact factor: 4.356

5.  Open-label uridine for treatment of depressed adolescents with bipolar disorder.

Authors:  Douglas G Kondo; Young-Hoon Sung; Tracy L Hellem; Kristen K Delmastro; Eun-Kee Jeong; Namkug Kim; Xianfeng Shi; Perry F Renshaw
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-04-12       Impact factor: 2.576

6.  Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of schizophrenia patients.

Authors:  P Bubber; V Hartounian; G E Gibson; J P Blass
Journal:  Eur Neuropsychopharmacol       Date:  2010-11-30       Impact factor: 4.600

7.  Effects of Mood Stabilizers on Brain Energy Metabolism in Mice Submitted to an Animal Model of Mania Induced by Paradoxical Sleep Deprivation.

Authors:  Emilio L Streck; Giselli Scaini; Gabriela C Jeremias; Gislaine T Rezin; Cinara L Gonçalves; Gabriela K Ferreira; Gislaine Z Réus; Wilson R Resende; Samira S Valvassori; Flávio Kapczinski; Mônica L Andersen; João Quevedo
Journal:  Neurochem Res       Date:  2015-04-17       Impact factor: 3.996

Review 8.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

9.  Comparison between cerebrospinal fluid and serum lactate concentrations in neurologic dogs with and without structural intracranial disease.

Authors:  Leontine Benedicenti; Giacomo Gianotti; Evelyn M Galban
Journal:  Can J Vet Res       Date:  2018-04       Impact factor: 1.310

10.  Differences at brain SPECT between depressed females with and without adult ADHD and healthy controls: etiological considerations.

Authors:  Ann Gardner; Dario Salmaso; Andrea Varrone; Alejandro Sanchez-Crespo; Susanne Bejerot; Hans Jacobsson; Stig A Larsson; Marco Pagani
Journal:  Behav Brain Funct       Date:  2009-09-01       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.